BPTH (Bio-Path Holdings) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bio-Path Holdings's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Bio-Path Holdings's long-term debt to total assets ratio declined from Sep. 2023 (0.01) to Sep. 2024 (0.00). It may suggest that Bio-Path Holdings is progressively becoming less dependent on debt to grow their business.

Bio-Path Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bio-Path Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings LT-Debt-to-Total-Asset Chart

Bio-Path Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

Bio-Path Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	-	-	-	-

Bio-Path Holdings LT-Debt-to-Total-Asset Calculation

Bio-Path Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.01	/	3.22
	=

Bio-Path Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	2.965
	=

Bio-Path Holdings (NAS:BPTH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bio-Path Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Executives

Aline Sherwood	director	347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen	director	1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese	director	4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen	director, officer: President, CEO & CFO	20651 PRINCE CREEK, KATY TX 77450
Paul Aubert	director	4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver	director	4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller	officer: COO & Secretary	17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison	director	2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris	director	550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read	director	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison	director	P O BOX 150248, OGDEN UT 84415